Antibody-drug conjugates as targeted therapies: Are we there yet? A critical review of the current clinical landscape.
ADC
Antibody-drug conjugate
Exposure-response
PK
Pharmacokinetics
Prodrug
Slow-release
Targeted drug delivery
Journal
Drug discovery today. Technologies
ISSN: 1740-6749
Titre abrégé: Drug Discov Today Technol
Pays: England
ID NLM: 101235076
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
29
06
2020
accepted:
15
07
2020
entrez:
13
12
2021
pubmed:
14
12
2021
medline:
15
12
2021
Statut:
ppublish
Résumé
Antibody-drug conjugates (ADCs) are targeted therapies with the expectation of broadened therapeutic window due to tumor-specific drug delivery. Recent approvals, including ADCs with a novel payload class, topoisomerase-1 inhibitors, generated renewed excitement in the field. We provide a critical review of approved and late-stage molecules, discuss strategies in solid tumors and ADCs outside oncology. Our pharmacokinetics-based assessment of targeting suggests that ADCs, especially in solid tumors, rely on additional mechanisms for efficacy including slow-release of the payload to the circulation at potentially efficacious levels. Further adjustments in the technology are needed to fulfill the promise of true targeted drug delivery.
Identifiants
pubmed: 34895651
pii: S1740-6749(20)30007-X
doi: 10.1016/j.ddtec.2020.07.002
pii:
doi:
Substances chimiques
Immunoconjugates
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
13-22Informations de copyright
Copyright © 2020 Elsevier Ltd. All rights reserved.